Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth A Erickson

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Annals of Surgery|August 7, 2018
A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal AdenocarcinomaSusan Tsai, Kathleen K Christians, Ben George, et al.
Surgery|October 31, 2002
Improved survival in resected biliary malignanciesAttila Nakeeb, Khoi Q Tran, Michael J Black, et al.
Annals of Surgical Oncology|February 14, 2023
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic CancerSam Z Thalji, Mandana Kamgar, Ben George, et al.
Journal of Surgical Oncology|March 24, 2023
Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantitySam Z Thalji, Mohammed Aldakkak, Kathleen K Christians, et al.
Frontiers in Oncology|May 5, 2020
Value of Pretreatment <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant TherapyChad A Barnes, Mohammed Aldakkak, Callisia N Clarke, et al.
Cancer Metastasis Reviews|October 6, 2021
Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technologyWilliam A Hall, Mandana Kamgar, Beth A Erickson, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2011
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancerStuart J Wong, Kathryn Winter, Neal J Meropol, et al.
Surgery|July 10, 2020
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancerChad A Barnes, Mohammed Aldakkak, Kathleen K Christians, et al.
Annals of Surgery|October 13, 2018
Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic CancerSusan Tsai, Ben George, David Wittmann, et al.
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancerStuart J Wong, Jennifer Moughan, Neal J Meropol, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Annals of Surgery|August 7, 2018
A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal AdenocarcinomaSusan Tsai, Kathleen K Christians, Ben George, et al.
Surgery|October 31, 2002
Improved survival in resected biliary malignanciesAttila Nakeeb, Khoi Q Tran, Michael J Black, et al.
Annals of Surgical Oncology|February 14, 2023
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic CancerSam Z Thalji, Mandana Kamgar, Ben George, et al.
Journal of Surgical Oncology|March 24, 2023
Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantitySam Z Thalji, Mohammed Aldakkak, Kathleen K Christians, et al.
Frontiers in Oncology|May 5, 2020
Value of Pretreatment <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant TherapyChad A Barnes, Mohammed Aldakkak, Callisia N Clarke, et al.
Cancer Metastasis Reviews|October 6, 2021
Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technologyWilliam A Hall, Mandana Kamgar, Beth A Erickson, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2011
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancerStuart J Wong, Kathryn Winter, Neal J Meropol, et al.
Surgery|July 10, 2020
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancerChad A Barnes, Mohammed Aldakkak, Kathleen K Christians, et al.
Annals of Surgery|October 13, 2018
Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic CancerSusan Tsai, Ben George, David Wittmann, et al.
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancerStuart J Wong, Jennifer Moughan, Neal J Meropol, et al.
Pageof 8